ICU sedation, delirium & recovery
Clinical characteristics and outcomes of immunocompromised critically ill patients with cytomegalovirus end-organ disease: a multicenter retrospective cohort study
Authors' conclusion
Mortality was high in critically ill, immunocompromised patients with CMV-EOD and varied considerably with the cause of immunodeficiency and organ involved by CMV.
Study context
- Population
- Adults with cytomegalovirus (CMV) end-organ disease admitted to 18 intensive care units (ICUs) in France, Israel and Spain, January 2010-December 2021; AIDS excluded
- Participants
- 185 adults
- Exposure
- Survivors vs non-survivors; risk factors for hospital mortality
- Outcome
- Hospital mortality
Methodological detailsmulticentre, international, observational
- Multicentre
- International
- Observational
Main finding
As reported in the abstract
Hospital mortality and independent risk factors
Odds ratio (95% CI)
Hematologic malignancy with active graft-versus-host disease
5.02(1.15–27.30)
CMV pneumonia
2.57(1.13–6.03)
Lymphocytes < 0.30 × 109/L at diagnosis of CMV-EOD
2.40(1.05–5.69)
Worse SOFA score at ICU admission
1.18(1.04–1.35)
Older age
1.04(1.01–1.07)
- Hospital mortality overall
- 61.4%
Observational data: associations, not effects.
Further findings
Hospital mortality by hematologic malignancy (subgroup)
P = 0.001
Type of CMV end-organ disease (CMV-EOD)
- Pneumonia
- 115, [62.2%]
- Pneumonia with a respiratory co-pathogen
- 55 [47.8%]
- CMV gastrointestinal disease
- 64 [34.6%]
- More than one organ involved
- 16 (8.8%)
Histopathological evidence
- Pneumonia
- 10/115 (8.7%)
- GI disease
- 43/64 (67.2%)
Other opportunistic infections
- Diagnosed
- 69 (37.3%)
Original publication
Clinical characteristics and outcomes of immunocompromised critically ill patients with cytomegalovirus end-organ disease: a multicenter retrospective cohort study. Crit Care. Published 16 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →